The optical and transport properties in the paramagnetic phase of a-RuC1, are studied here for the first time. Values are reported for the dc conductivity of single crystals over the temperature range 110 to 500 OK in the two crystallographic directions, along and perpendicular to the optic c-axis: at 300 OK, ellc = 8 x 10' Rcm and e l c = 1.7 x 108 Rcm. The activation energy for both directions is = 0.1 eV below 300 OK and = 0.5 eV for temperatures above 400 OK. Detailed absorption spectra in the energy range 0.1 to 4 eV, and in the temperature interval 80 to 300 OK, reveal three weak bands (a = 10s om-l) a t = 0.28, 0.53, and 0.75 eV, two stronger peaks (a z lo4 to lo6 cm-l) at = 1.18, 2.08 and a step at 3.10 eV (values at 80°K). Reflectivity measurementsin the energy range 1 to 9 eV show maxima which, at 300OK, are centred at = 1.1, 1.9, and 3.10 eV and a marked reflection peak, at z 5.10 eV, probably related to p(c1) + s(Ru) band-to-band transitions. Ac photoconductivity spectra in the 0.6 to 2.8 eV region show structures closely related to the absorption bands in the same energy range. The different temperature dependence of the absorption and photocurrent spectra over the 80 to 300 O K interval is discussed. After an analysis of the transport data, the absorption spectrum up to 3 eV is discussed in terms of the Tanabe and Sugano diagram for a d6 configuration.Les propri6tes optiques et Blectriques de la phase paramagnetique du RuCl,-a ont 6t6 6tudi6es dans ce travail pour la premi&re fois. Nous avons report6 les valeurs de la conductivit6 Blectrique de cristaux de RuCl,-a entre 110 et 500 "K dans les deux directions cristal-
Pediatric-onset HCM is rare and associated with adverse outcomes driven mainly by arrhythmic events. Risk extends well beyond adolescence, which calls for unchanged clinical surveillance into adulthood. In this study, predictors of adverse outcomes differ from those of adult populations with HCM. In secondary prevention, the implantable cardioverter defibrillator did not confer absolute protection in the presence of limiting symptoms of heart failure.
Controversial data exist about the long-term results of aortic coarctation (AC) repair. This study explored the prevalence and predictors of left ventricular (LV) hypertrophy, late hypertension, and hypertensive response to exercise in 48 subjects (age, 15.1 ± 9.7 years) currently followed in the authors' tertiary care hospital after successful AC repair. Data on medical history, clinical examination, rest and exercise echocardiography, and ambulatory blood pressure monitoring were collected. The time from AC repair to follow-up evaluation was 12.9 ± 9.2 years. The prevalence of LV hypertrophy ranged from 23 to 38 %, based on the criteria used to identify LV hypertrophy, and that of concentric geometry was 17 %. One sixth of the patients without residual hypertension experienced late-onset hypertension. One fourth of those who remained normotensive without medication showed a hypertensive response to exercise. Age at AC repair was the strongest independent predictor of LV hypertrophy, defined using indexation either for body surface area (odds ratio [OR], 1.03; p = 0.0090) or for height(2.7) (OR 1.02; p = 0.029), and it was the only predictor of late hypertension (OR 1.06; p = 0.0023) and hypertensive response to exercise (OR 1.09; p = 0.029). The risk of LV hypertrophy was 25 % for repair at the age of 3.4 years but rose to 50 and 75 % for repair at the ages of 5.9 and 8.4 years, respectively. Similar increases were found for the risk of late-onset hypertension and hypertensive response to exercise. A considerable risk of LV hypertrophy, late hypertension, and hypertensive response to exercise exists after successful AC repair. Older age at intervention is the most important predictor of these complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.